

STANDARD TREATMENT WORKFLOW (STW)

Sickle Cell Disease

Tulika Seth¹, Dipti Jain², Manisha Madkaikar³, N S Chatterjee⁴, P K Patra⁵, Roshan Colah⁶

¹All India Institute of Medical Science, New Delhi; ²Govt Medical College, Nagpur; ³Indian Council of Medical Research-National Institute of Immunohaematology Mumbai; ⁴Indian Council of Medical Research, New Delhi; ⁵Chandulal Chandrakar Memorial Government Medical College; ⁶Indian Council of Medical Research-National Institute of Immunohaematology Mumbai

CORRESPONDING AUTHOR

Dr Tulika Seth, Department of Haemolytic Anaemia, All India Institute of Medical Science, New Delhi
Email: drtulikaseth@gmail.com

CITATION

Seth T, Jain D, Madkaikar M, Chatterjee NS, Patra PK, Colah R. Sickle Cell Disease. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S49-S50.

DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.025>

This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access


DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.

0202/2024



Standard Treatment Workflow (STW) SICKLE CELL DISEASE ICD-10-D57

**LEGEND**

**Standard Treatment Workflow (STW)****SICKLE CELL DISEASE****ICD-10-D57**

GENERAL INTRODUCTION	SUBTYPES			MANIFESTATIONS OF VOC	
<ul style="list-style-type: none">• Hemolytic anemia, where RBCs sickle under hypoxia or stress. Sickling and inflammation lead to vaso-occlusive crisis (VOC) and organ damage• Autosomal recessive - mutations in the β-globin gene• ~88% of sickle homozygous cases in Asia are Indians	<div>Carriers/ heterozygous (HbAS)</div> <div>Have only one disease allele, usually asymptomatic</div>	<div>Disease/ sufferer/ homozygous (HbSS)</div> <div>Have both defective alleles, usually symptomatic</div>	<div>Other symptomatic genetic variants</div> <div>HbS-β thalassemia, HbSD-Punjab disease, HbSE disease etc.</div>	<ul style="list-style-type: none">• Experienced as pain, or swelling• Each VOC can lead to long lasting problems and end-organ damage• Typical sites - hands and feet, limbs, abdominal viscera, ribs, sternum etc• The crisis is usually precipitated by fever, strenuous exercise, dehydration, drenching in rain, surgery, infection etc.	
THIS FAMILY TREE SHOWS THROUGH MENDELIAN TRANSMISSION - THE RISK OF HAVING AFFECTED CHILDREN ACROSS GENERATION IN PARENTS WITH SCD - HETEROZYGOUS AND HOMOZYGOUS.					
<div>LEGEND</div> <ul style="list-style-type: none">• Half red color – one affected allele - carrier (HbAS)• Full red color – two affected alleles - homozygous/ diseased (HbSS)• No red color – both alleles normal					
CLINICAL MANIFESTATIONS OF SCD		Target group to be screened	Tests / remarks		
<ul style="list-style-type: none">• Common presentations - Pain, anemia, icterus, increased risk of infection• Acute morbidity/ events - Splenic sequestration, fatigue, acute chest syndrome, priapism• Long term complications - End organ damage, hepatopathy, chronic kidney disease, hypersplenism, avascular necrosis of femur, osteomyelitis, pulmonary hypertension, cholelithiasis, functional disability, retinopathy, foot ulcers- refer to a higher center for adequate management		Antenatal Mothers or pre-pregnancy planning	<ul style="list-style-type: none">• CBC all women in first trimester• In endemic pockets/ high risk population: solubility test/ POC tests for sickle cell• Or HPLC and electrophoresis, if available<ul style="list-style-type: none">• If mother is a sickle cell carrier/ disease,• Then testing of father is mandatory,• Ideally by HPLC, if not available refer to higher center• If father tests positive, counselling and pre-natal testing should be performed (at centers with necessary facilities) to prevent risk of birth of affected newborn		
		Newborn	<ul style="list-style-type: none">• POC tests to initiate penicillin prophylaxis in baby and enrolling vaccination program• HPLC and electrophoresis, if available or at later date		
		Population screening/ patient of any age	<ul style="list-style-type: none">• In endemic pockets/ high risk population: solubility test/ POC tests for sickle cell		
GENERAL PRINCIPALS OF MANAGEMENT			PROPHYLAXIS FOR ALL SCD PATIENTS		
<ul style="list-style-type: none">• Carriers are usually asymptomatic and needs no treatment• The goal of management is to improve quality of life and life expectancy of the affected individuals• Episodes of fever have to be dealt with early and aggressively• Early and aggressive management of pain should be advocated, since pain may be indicative of microvascular organ damage. Pain management using paracetamol, diclofenac or tramadol. For severe pain, refer to higher centre• Malaria in SCD patients will be present with same frequency as endemic prevalence• Evaluate for anaemia. Iron supplements for anemia to be used cautiously (low dose - not more than 3 months). Other nutritional causes (Vit B12, and Folic acid deficiency) and infectious causes (worm infestations) to be evaluated• Prophylaxis for infections- penicillin, immunizations and folic acid supplement, disease modifying agents like hydroxyurea (HU) and blood transfusions have specific indications• Acute morbidity events occur over the lifetime and require management, regular monitoring may help to reduce severity of complications• Only curative therapy is hematopoietic stem cell transplantation. This is recommended and beneficial in a small subset of patients not responding to HU or newer disease modifying agents			New born HbSS till 5 years of age	Penicillin prophylaxis- 65mg BD, less than 12 months 125 mg BD till 2 years , then 250mg BD till 5 years lifelong if post splenectomy	
			To prevent megaloblastic crises	Folic acid- less than 1 year of age, 2.5 mg daily 1 year of age, 5 mg daily	
			Common recommended vaccinations	Pneumococcal Vaccine H-influenza vaccine Typhoid Vaccine Influenza vaccine COVID 19 vaccine	
HOW TO PRESCRIBE HYDROXYUREA				Red Flag for hospitalization or referral to higher centre	EDUCATION AND GENETIC COUNSELING
Indications for HU	Baseline Investigations	Dosing	Toxicity	<ul style="list-style-type: none">• Acute illness requiring immediate medical care, including emergencies• Persistent Temperature $>38^{\circ}\text{C}$• Pain inadequately relieved by home measures• Significant respiratory symptoms (cough, shortness of breath, chest pain) or hypoxia• Abdominal pain, distention, acute enlargement of spleen• Any neurological signs or symptoms• Significant increase in pallor, fatigue, lethargy• Significant vomiting and diarrhoea	<ul style="list-style-type: none">• Medical disease counselling - Explain the clinical presentation, severity, consequences of the disease. Importance of early diagnosis by newborn screening and comprehensive care. Teach patients and parents –avoid infections, be adequately hydrated, balanced nutrition, avoid over exercise, 9avoid extreme temperatures, importance of penicillin prophylaxis, need for regular clinical follow up of patients• Genetic counselling - Explain carrier state and risk of having an affected child. Document family history, consanguinity. draw a pedigree chart, explain the inheritance pattern and risk of recurrence• Preconception care counselling - for at-risk couples by following recommended practices. Give options and referrals• Pre and post test support to the family - while making decisions and eliminating irrational fears, stigmatization, maintaining confidentiality• Cascade screening - Emphasize the need for screening of extended family members
<ul style="list-style-type: none">• Above 2 years of Age• All children more than 9 months of age may be offered	<ul style="list-style-type: none">• Complete physical Examination• CBC• Liver function test• Renal function• Pregnancy test for relevant population	<ul style="list-style-type: none">• Infants and Children: 10-15 mg/kg/day• Adolescents: 15mg/kg/day• Dose escalation by 5 mg/kg; 2-3 months only in definite indications• CBC monitoring 1-3 months when starting the medicine or if dose change	<ul style="list-style-type: none">• Common dose dependent toxicity: anaemia, nausea, diarrhoea, gastritis• Nail/ skin hyperpigmentation• Long term toxicity: Mucositis or leg ulcers		
EARLY AND AGGRESSIVE MANAGEMENT OF PAIN AND INFECTIONS WILL HELP IMPROVE LONG TERM OUTCOME					

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.icmr.org.in) for more information.

©Department of Health Research, Ministry of Health & Family Welfare, Government of India.